Developing a comprehensive response for treatment of children under 6 years of age with schistosomiasis: research and development of a pediatric formulation of praziquantel

by Jutta Reinhard-Rupp and Katharina Klohe
Infectious Diseases of Poverty, 2017 6:122 – Published: 3 August 2017

4 pp. 513 kB
https://idpjournal.biomedcentral.com/track/pdf/10.1186/s40249-017-0336-9?
site=idpjournal.biomedcentral.com

According to 2017 World Health Organization (WHO) estimates 220 million people are potentially infected with schistosomiasis, from which probably 10% are children under 6 years of age. The regular treatment approach of a single, oral dose of 40 mg/kg body weight with praziquantel however, is difficult for children under the age of 6, leaving them without a treatment option. In order to address this important gap in treatment target populations, an international public-private partnership that works on a not-for-profit basis in the field of drug research and development for schistosomiasis was established in 2012. This is called the Pediatric Praziquantel Consortium. Its mission was and continues to be to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children (3–6 months up to 6 years).

(Visited 7 times, 1 visits today)
This entry was posted in Essential Medicines, General, Other Infectious Diseases. Bookmark the permalink.